DocGo (NASDAQ:DCGO) Receives Buy Rating from Stifel Nicolaus

Stifel Nicolaus reissued their buy rating on shares of DocGo (NASDAQ:DCGO) in a research report report published on Monday, Benzinga reports. They currently have a $12.00 price target on the stock.

A number of other equities analysts have also weighed in on the stock. BTIG Research initiated coverage on shares of DocGo in a research note on Friday, August 18th. They issued a buy rating and a $15.00 target price for the company. Needham & Company LLC restated a buy rating and set a $14.00 price objective on shares of DocGo in a research note on Monday. Northland Securities increased their price objective on shares of DocGo from $15.00 to $16.00 in a research note on Tuesday, August 8th. Finally, Cantor Fitzgerald restated an overweight rating and set a $13.00 price objective on shares of DocGo in a research note on Thursday, September 14th.

DocGo Stock Performance

DCGO stock opened at $5.29 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.56 and a quick ratio of 2.56. The company has a 50 day moving average price of $8.60 and a 200 day moving average price of $8.69. DocGo has a fifty-two week low of $4.88 and a fifty-two week high of $11.41. The stock has a market capitalization of $549.05 million, a PE ratio of 75.57 and a beta of 0.85.

DocGo (NASDAQ:DCGO) last issued its earnings results on Monday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). DocGo had a net margin of 1.27% and a return on equity of 3.20%. The business had revenue of $125.49 million for the quarter, compared to the consensus estimate of $119.64 million. Analysts forecast that DocGo will post 0.09 EPS for the current year.

Insider Activity

In other news, insider Adriaan Stephanus Oberholzer sold 50,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $10.15, for a total value of $507,500.00. Following the sale, the insider now directly owns 1,193,413 shares of the company’s stock, valued at approximately $12,113,141.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Adriaan Stephanus Oberholzer sold 50,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $10.15, for a total value of $507,500.00. Following the sale, the insider now directly owns 1,193,413 shares of the company’s stock, valued at approximately $12,113,141.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Ely D. Tendler sold 10,000 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $8.75, for a total transaction of $87,500.00. Following the completion of the transaction, the general counsel now directly owns 23,088 shares in the company, valued at $202,020. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,000 shares of company stock valued at $613,000. 13.78% of the stock is owned by company insiders.

Institutional Trading of DocGo

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of DocGo by 17.7% during the first quarter. BlackRock Inc. now owns 1,156,560 shares of the company’s stock valued at $10,699,000 after acquiring an additional 174,087 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of DocGo by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,049,027 shares of the company’s stock valued at $9,704,000 after acquiring an additional 14,704 shares during the last quarter. Ergoteles LLC bought a new position in shares of DocGo during the first quarter valued at $333,000. Lazard Asset Management LLC raised its stake in shares of DocGo by 99.3% during the first quarter. Lazard Asset Management LLC now owns 10,799 shares of the company’s stock valued at $99,000 after acquiring an additional 5,381 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in DocGo by 2.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 380,127 shares of the company’s stock worth $3,517,000 after buying an additional 9,397 shares during the last quarter. Institutional investors and hedge funds own 52.14% of the company’s stock.

About DocGo

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.